Indaptus Therapeutics

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association for Cancer Research (AACR) has accepted an abstract on its Decoy anti-tumor platform for its annual scientific conference on April 14-19, 2023 in Orlando.

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that Atlanta, Ga.-based Emory Winship Cancer Institute (“Emory”) has become a new clinical trial site for INDP-D101. INDP-D101 is the Company's first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. Emory has begun screening patients.

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

First Dose Initial Side-Effect Profile Consistent with Expected Outcome First Dose Initial Side-Effect Profile Consistent with Expected Outcome

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has named Robert Martell, M.D., Ph.D. to its Board of Directors.

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101. INDP-D101 is the Company's first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. Patient screening at the Morristown, NJ hospital is expected soon.

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the initiation of INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. The USC Norris Cancer Center in Los Angeles, California is the first activated clinical trial site that has been opened for patient enrollment, and patient screening is expected soon.

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Company Remain s On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micro Main Event XV. The conference is being held on October 25 – 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Indaptus Therapeutics to Present at the LD Micro Main Event XV

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference. The conference is being held on September 12 – 14 at the Lotte New York Palace Hotel.

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022 at 2:30 p.m. ET in New York City.

Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:45 p.m. ET.

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

Mullen Automotive

NeuroMetrix

Here are three penny stocks for your watchlist right now The post Hot Penny Stocks to Watch Right Now? 3 For Your List in May appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch Right Now? 3 For Your List in May

Indaptus Therapeutics (INDP) stock is soaring higher on Thursday following an update from the U.S. Food and Drug Administration (FDA). The post Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today?

Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today?

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed. The Company plans to initiate the clinical trial in the second half of 2022.

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 8:30am ET.

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

Announces Submission of Investigational New Drug (IND) Application for Decoy20

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update.

Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING & TLR-Targeting Therapies Summit taking place virtually from March 22-24, 2022.

Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in an on demand pre-recorded presentation at the 34th Annual ROTH Conference which is taking place March 14 – 15, 2022.

Indaptus Therapeutics to Present at 34th Annual ROTH Conference

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET.

Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience

Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer

NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the third quarter ended September 30, 2021 and provides a corporate update.

Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Maxim analyst has upgraded Indaptus Therapeutics Inc (NASDAQ: INDP) to Buy from Hold with a $16 price target, an upside of over 100%. Analyst Jason McCarthy says, Indaptus is leveraging the ability of attenuated, non-pathogenic gram-negative bacteria to stimulate both innate and adaptive immune responses for oncology indications and infectious diseases.

News for Indaptus Therapeutics Stock (INDP)